U.S. Markets close in 2 hrs 31 mins
  • S&P 500

    +39.95 (+1.06%)
  • Dow 30

    +321.86 (+1.05%)
  • Nasdaq

    +99.14 (+0.90%)
  • Russell 2000

    +19.77 (+1.16%)
  • Crude Oil

    +1.87 (+1.72%)
  • Gold

    +5.90 (+0.33%)
  • Silver

    +0.19 (+0.98%)

    +0.0001 (+0.0104%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -2.01 (-7.00%)

    +0.0006 (+0.0484%)

    +0.4920 (+0.3640%)

    -180.80 (-0.91%)
  • CMC Crypto 200

    +0.70 (+0.17%)
  • FTSE 100

    +64.00 (+0.89%)
  • Nikkei 225

    +218.19 (+0.84%)

Transine Therapeutics poised for growth with new CSO hire and tripling of lab space

·2 min read

Andy Billinton PhD appointed as Chief Scientific Officer

Expansion into larger facilities at the Babraham Research Campus

CAMBRIDGE, England, June 23, 2022--(BUSINESS WIRE)--Transine Therapeutics today announced the appointment of Andy Billinton as Chief Scientific Officer as it triples its facility footprint at The Babraham Research Campus.

Transine Therapeutics is developing a novel class of therapeutic RNAs (SINEUPs®) capable of upregulating protein expression with a superior level of control and specificity across an unprecedented range of hard-to-treat diseases, which have been beyond the reach of small molecules, conventional biologics, or gene therapies.

The appointment of Andy as CSO comes at a time of rapid growth for the company following its successful £13.7m extended seed financing to accelerate its platform and portfolio development, plus a three-fold expansion of its lab and office facilities in the heart of the Cambridge life science cluster at the Babraham Research Campus.

Andy has more than 20-years’ experience in drug discovery and early development, driving programmes from inception, though candidate selection and into clinical development. He joins Transine from NodThera, where he led translational efforts on multiple molecules which entered Phase 1 for indications related to innate immunity, including neuroinflammation.

Prior to this, Andy led the Neuroscience Discovery Group at MedImmune/AstraZeneca, worked with GSK targeting neurological and pain indications from idea through to Phase 2, and co-founded Transpharmation; a boutique CRO which works with academic, biotech and pharma clients to deliver bespoke in vivo model solutions. Andy holds a PhD in neuropharmacology from the University of Birmingham.

Jan Thirkettle, CEO of Transine, said: "We are thrilled and very fortunate to have Andy join Transine. His experience, skill and passion bring innumerable benefits to the team and to our mission to develop life-changing therapeutics for serious, underserved diseases.

"Our robust seed financing, with the addition of a new investor, and recent hiring of a number of talented individuals from academia and industry has put us in a strong position to progress our pipeline. With Andy on board to pilot our next phase of scientific progression and the fantastic facilities we now have; we are set to assess new opportunities to further leverage our unique SINEUP® platform."

Andy adds: "I am delighted to be joining such an outstanding and visionary team to help realise the incredible potential of this technology and to achieve meaningful benefit for patients.

"I’m intrigued and motivated by the prospect of dialling up protein translation in a specific, controlled manner and believe that Transine has a real and exciting opportunity to bring SINEUPs forward as a novel therapeutic modality for hard-to-treat diseases."


About Transine® Therapeutics

Transine Therapeutics is an RNA platform company developing a novel class of therapeutic RNAs (SINEUPs) capable of upregulating protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. Conceived to boost the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation, our SINEUP® platform allows us to address diseases which, until now, have been beyond the reach of small molecules, conventional biologics or gene therapies. Our proprietary technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. Our talented team of researchers and drug developers combines significant expertise spanning RNA biology, drug discovery and the commercialisation of new platforms, and our ambitious plans are supported by a passionate group of investors who recognise the broad potential of our platform.

For more information, please visit: www.transinetx.com

TRANSINE and SINEUP are trademarks of Transine Therapeutics Limited.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005416/en/


Transine Therapeutics
Sarah Brereton, Director, Limewash
Tel: +44 (0)7796 583 223
Email: sarah@limewash.co.uk